drug · antibody drug conjugate
raludotatug deruxtecan
Phase 3updated 5mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Antibody drug conjugate drug with a maximum clinical stage of Phase 2, with 1 investigational indication.
indications
indications
NSCLC
all catalysts(1)
Trials studying raludotatug deruxtecan
- phase2A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- phase2A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
- phase2A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
News(1)
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealDaiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.fiercebiotech · 7d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that